CDK12 and neoplasm: Pharmacologic inhibition of CDK12 with THZ-531 reverses this transcriptional balance, downregulating DDR and cell-cycle genes while upregulating AP-1 and NF-κB targets, thereby promoting apoptosis and loss of tumor viability [44].